Malastad (Proguanil Hydrochloride, Atovaquone)

Atovaquone blocks mitochondrial electron transport in the malaria parasite, disrupting its energy production. Proguanil is converted in the body to cycloguanil, which inhibits the parasite’s dihydrofolate reductase enzyme, preventing folate synthesis. Together, they halt parasite growth and lead to its death.

The specific dose of Malastad is determined by the prescribing clinician based on the patient’s age, weight, indication (pre‑exposure prophylaxis or treatment), and local resistance patterns. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety data for Malastad in pregnancy are limited, and it is generally not recommended unless the potential benefit justifies the risk. During breastfeeding, the drug may be excreted in milk, so caution is advised and a healthcare professional should evaluate the risk‑benefit balance.

To order Malastad, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Malastad combines two mechanisms of action, offering a broader spectrum and reduced risk of resistance compared with single‑agent therapies such as chloroquine or mefloquine. It is often preferred for travelers and in regions where resistance to older drugs is common, though cost and local guidelines may influence choice.

Malastad tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Malastad is taken orally with food or a milky drink to enhance absorption. For prophylaxis, it is usually started 1–2 days before entering a malaria‑risk area and continued for 7 days after leaving. For treatment, it is taken as directed by a healthcare professional for the full prescribed course.

Serious risks, though rare, include severe hypersensitivity reactions such as anaphylaxis, Stevens‑Johnson syndrome, hepatic dysfunction, hemolytic anemia, and severe neutropenia. Patients should seek immediate medical attention if they experience signs of a serious allergic reaction, jaundice, dark urine, or unexplained bleeding.

Malastad should be avoided in individuals with known hypersensitivity to atovaquone, proguanil, or any component of the formulation. It is also contraindicated in patients with severe renal or hepatic impairment unless closely monitored, and it should not be used as monotherapy in areas with documented resistance.